Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
D. Chau, D. L. Becker, M. E. Coombes, G. Ioannidis, J. D. Adachi & R. Goeree. (2012) Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada. Journal of Medical Economics 15:sup1, pages 3-14.
Read now
Read now
R. Akehurst, N. Brereton, R. Ariely, T. Lusa, M. Groot, P. Foss & S. Boonen. (2011) The cost effectiveness of zoledronic acid 5 mg for the management of postmenopausal osteoporosis in women with prior fractures: evidence from Finland, Norway and the Netherlands. Journal of Medical Economics 14:1, pages 53-64.
Read now
Read now
Articles from other publishers (35)
Ron Goeree, Natasha Burke, Manon Jobin, Jacques P. Brown, Donna Lawrence, Björn Stollenwerk, Damon Willems & Ben Johnson. (2022) Cost-effectiveness of romosozumab for the treatment of postmenopausal women at very high risk of fracture in Canada. Archives of Osteoporosis 17:1.
Crossref
Crossref
Yoko Koide, Yu Kataoka, Takeshi Hasegawa, Erika Ota & Hisashi Noma. (2022) Effect of systemic bisphosphonate administration on patients with periodontal disease: a systematic review and meta-analysis protocol. BMJ Open 12:3, pages e057768.
Crossref
Crossref
Kensuke Moriwaki. 2022. Osteoporotic Fracture and Systemic Skeletal Disorders. Osteoporotic Fracture and Systemic Skeletal Disorders
473
480
.
Ryuji Osawa, Shota Ikegami, Hiroshi Horiuchi, Ryosuke Tokida, Hiroyuki Kato & Jun Takahashi. (2021) Osteoporosis Detection by Physical Function Tests in Resident Health Exams: A Japanese Cohort Survey Randomly Sampled from a Basic Resident Registry. Journal of Clinical Medicine 10:9, pages 1896.
Crossref
Crossref
E Michael Lewiecki, Jesse D Ortendahl, Jacqueline Vanderpuye‐Orgle, Andreas Grauer, Jorge Arellano, Jeffrey Lemay, Amanda L Harmon, Michael S Broder & Andrea J Singer. (2019) Healthcare Policy Changes in Osteoporosis Can Improve Outcomes and Reduce Costs in the United States. JBMR Plus 3:9.
Crossref
Crossref
Anna N.A. Tosteson. 2018. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism
597
602
.
M. Kastner, L. Perrier, S. E. P. Munce, C. C. Adhihetty, A. Lau, J. Hamid, V. Treister, J. Chan, Y. Lai & S. E. Straus. (2017) Complex interventions can increase osteoporosis investigations and treatment: a systematic review and meta-analysis. Osteoporosis International 29:1, pages 5-17.
Crossref
Crossref
Monika Kastner, Anna M Sawka, Jemila Hamid, Maggie Chen, Kevin Thorpe, Mark Chignell, Joycelyne Ewusie, Christine Marquez, David Newton & Sharon E Straus. (2014) A knowledge translation tool improved osteoporosis disease management in primary care: an interrupted time series analysis. Implementation Science 9:1.
Crossref
Crossref
Sang-Rim KimYong-Geun ParkSoo Yong KangKwang Woo NamYong-Gum ParkYong-Chan Ha. (2014) Undertreatment of Osteoporosis Following Hip Fractures in Jeju Cohort Study. Journal of Bone Metabolism 21:4, pages 263.
Crossref
Crossref
N G Mokrysheva & L Ya Rozhinskaya. (2013) MODERN VIEW ON THE EFFECTIVENESS OF THERAPY FOR POSTMENOPAUSAL OSTEOPOROSIS. INNOVATIVE DRUGS OF TARGETED ACTION. Osteoporosis and Bone Diseases 16:1, pages 29-33.
Crossref
Crossref
W. D. Leslie, S. L. Brennan, L. M. Lix, H. Johansson, A. Oden, E. McCloskey & J. A. Kanis. (2013) Direct comparison of eight national FRAX® tools for fracture prediction and treatment qualification in Canadian women. Archives of Osteoporosis 8:1-2.
Crossref
Crossref
Alice Smith, Brittany Shaw, Danielle Laliberte, Jennifer Langston & Reamer L. Bushardt. (2013) Rethinking osteoporosis. Journal of the American Academy of Physician Assistants 26:8, pages 20-27.
Crossref
Crossref
Anna N.A. Tosteson. 2013. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism
455
460
.
Ronald C. Wielage, Megha Bansal, J. Scott Andrews, Robert W. Klein & Michael Happich. (2013) Cost-Utility Analysis of Duloxetine in Osteoarthritis: A US Private Payer Perspective. Applied Health Economics and Health Policy 11:3, pages 219-236.
Crossref
Crossref
Ronald Wielage, Megha Bansal, Kinsley Wilson, Robert Klein & Michael Happich. (2013) Cost-Effectiveness of Duloxetine in Chronic Low Back Pain. Spine 38:11, pages 936-946.
Crossref
Crossref
Ronald C. Wielage, Megha Bansal, J. Scott Andrews, Madelaine M. Wohlreich, Robert W. Klein & Michael Happich. (2013) The Cost-Effectiveness of Duloxetine in Chronic Low Back Pain: A US Private Payer Perspective. Value in Health 16:2, pages 334-344.
Crossref
Crossref
Léon Nshimyumukiza, Audrey Durand, Mathieu Gagnon, Xavier Douville, Suzanne Morin, Carmen Lindsay, Julie Duplantie, Christian Gagné, Sonia Jean, Yves Giguère, Sylvie Dodin, François Rousseau & Daniel Reinharz. (2013) An economic evaluation: Simulation of the cost‐effectiveness and cost‐utility of universal prevention strategies against osteoporosis‐related fractures. Journal of Bone and Mineral Research 28:2, pages 383-394.
Crossref
Crossref
R. B. Hopkins, E. Pullenayegum, R. Goeree, J. D. Adachi, A. Papaioannou, W. D. Leslie, J. E. Tarride & L. Thabane. (2011) Estimation of the lifetime risk of hip fracture for women and men in Canada. Osteoporosis International 23:3, pages 921-927.
Crossref
Crossref
Monika Kastner, Anna Sawka, Kevin Thorpe, Mark Chignel, Christine Marquez, David Newton & Sharon E Straus. (2011) Evaluation of a clinical decision support tool for osteoporosis disease management: protocol for an interrupted time series design. Implementation Science 6:1.
Crossref
Crossref
Jacques P. Brown, J.D. Adachi, D.L. Kendler, R. Rigal, G. Deutsch & J.M. Leclerc. (2011) A community-based clinical trial of Intra-Venous zOledRonic acid once Yearly in comparison to oral bisphosphonates in postmenopausal women with osteoporosis: The IVORY trial. Contemporary Clinical Trials 32:5, pages 741-746.
Crossref
Crossref
André Barkhordarian, Reem Ajaj, Manisha H. Ramchandani, Gary Demerjian, Riana Cayabyab, Sohrab Danaie, Nora Ghodousi, Natasha Iyer, Nicole Mahanian, Linda Phi, Amy Giroux, Ercolano Manfrini, Negoita Neagos, Muniza Siddiqui, Olivia S. Cajulis, Xenia M. C. Brant, Paul Shapshak & Francesco Chiappelli. (2011) Osteoimmunopathology in HIV/AIDS: A Translational Evidence-Based Perspective. Pathology Research International 2011, pages 1-13.
Crossref
Crossref
L.-A. Fraser, L. Langsetmo, C. Berger, G. Ioannidis, D. Goltzman, J. D. Adachi, A. Papaioannou, R. Josse, C. S. Kovacs, W. P. Olszynski, T. Towheed, D. A. Hanley, S. M. Kaiser, J. Prior, S. Jamal, N. Kreiger, J. P. Brown, H. Johansson, A. Oden, E. McCloskey, J. A. Kanis & W. D. Leslie. (2010) Fracture prediction and calibration of a Canadian FRAX® tool: a population-based report from CaMos. Osteoporosis International 22:3, pages 829-837.
Crossref
Crossref
Hilal Maradit Kremers, Sherine E. Gabriel & Michael F. Drummond. 2011. Rheumatology. Rheumatology
23
28.e5
.
Francesco ChiappelliFrancesco Chiappelli. 2011. Osteoimmunopathology. Osteoimmunopathology
69
100
.
Monika Kastner, Jamy Li, Danielle Lottridge, Christine Marquez, David Newton & Sharon E Straus. (2010) Development of a prototype clinical decision support tool for osteoporosis disease management: a qualitative study of focus groups. BMC Medical Informatics and Decision Making 10:1.
Crossref
Crossref
M. Ivergård, O. Ström, F. Borgström, R.T. Burge, A.N.A. Tosteson & J. Kanis. (2010) Identifying cost-effective treatment with raloxifene in postmenopausal women using risk algorithms for fractures and invasive breast cancer. Bone 47:5, pages 966-974.
Crossref
Crossref
Patrizia Berto, Stefania Maggi, Marianna Noale & Stefania Lopatriello. (2013) Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis. Aging Clinical and Experimental Research 22:2, pages 179-188.
Crossref
Crossref
Valentina I. Petkov & Melissa I. Williams. 2010. Osteoporosis. Osteoporosis
605
620
.
Luc Bonneville & Isaac Nahon-Serfaty. (2009) Consommation de médicaments au Canada : le rôle des stratégies de communication de l’industrie pharmaceutiqueMedication use in Canada: the role of communication strategies in the pharmaceutical industry. Communiquer. Revue de communication sociale et publique:2, pages 55-76.
Crossref
Crossref
O. Sheehy, C. Kindundu, M. Barbeau & J. LeLorier. (2009) Adherence to weekly oral bisphosphonate therapy: cost of wasted drugs and fractures. Osteoporosis International 20:9, pages 1583-1594.
Crossref
Crossref
PM Ciaschini, SE Straus, LR Dolovich, RA Goeree, KM Leung, CR Woods, GM Zimmerman, SR Majumdar, S Spadafora, LA Fera & HN Lee. (2008) Community-based randomised controlled trial evaluating falls and osteoporosis risk management strategies. Trials 9:1.
Crossref
Crossref
Anna N. A. Tosteson. 2008. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism
256
260
.
Kurt Lippuner, Albrecht Popp, Thomas Szucs & Matthias Schwenkglenks. (2013) Kosteneffektivität einer Osteoporose-Behandlung nach systematischem Bevölkerungsscreening in der Schweiz: Auswirkungen der Preisreduktion des Alendronat-OriginalpräparatesCost-effectiveness of osteoporosis treatment following systematic population screening in Switzerland: Impact of the price reduction of the original brand of alendronate. PharmacoEconomics German Research Articles 6:1, pages 19-28.
Crossref
Crossref
Eric S Meadows, Robert Klein, Matthew D Rousculp, Lee Smolen, Robert L Ohsfeldt & Joseph A Johnston. (2007) Cost-effectiveness of preventative therapies for postmenopausal women with osteopenia. BMC Women's Health 7:1.
Crossref
Crossref
M. Schwenkglenks & K. Lippuner. (2007) Simulation-based cost-utility analysis of population screening-based alendronate use in Switzerland. Osteoporosis International 18:11, pages 1481-1491.
Crossref
Crossref